CNSY:NASDAQ, Cerenome Inc Com Par $0.0001 (New) Jan 2026

Why CNSY stock rose on November 13

Cerenome Inc Com Par $0.0001 (New) Jan 2026 rose 23.3% on Friday, November 13, 2026, on 8,014,326 shares, 10 times its average daily volume. Headlines around the move:

CNSY stock overview

Cerenome Inc Com Par $0.0001 (New) Jan 2026 (CNSY:NASDAQ) closed at $0.950 on November 13, 2026, up 23.32% on the day. The stock trades 95.0% below its 52-week high of $19.00 and 121.0% above its 52-week low of $0.430. Over the past year, it lost 84.8%. Cerenome Inc Com Par $0.0001 (New) Jan 2026 is part of the Health Care sector.

Key figures

Price
$0.950
Day change
+23.32%
Volume
8,014,326
Average volume
767,132
Market cap
7M+
52-week range
$0.430 – $19.00
50-day average
$1.70
200-day average
$4.33

Price action over the past year

In 193 trading sessions since February 10, 2026, CNSY closed higher on 75 days (39%). Its best day was April 9, 2026 (+23.66%) and its worst was November 4, 2026 (-31.54%). The stock moved 10% or more in a single session 21 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

CNSY news

About Cerenome Inc Com Par $0.0001 (New) Jan 2026

Plus Therapeutics, Inc. (NASDAQ: PSTV) is a clinical-stage healthcare company advancing an integrated approach to central nervous system ('CNS') cancers through precision therapeutics, molecular diagnostics and data-driven technologies. The Company's lead therapeutic platform, REYOBIQ¿ (rhenium Re186 obisbemeda), is being developed for the treatment of leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancers. Its CNSide® cerebrospinal fluid assay platform is designed to provide diagnostic and disease monitoring information to support the management of patients with CNS cancers. Together with its growing data and artificial intelligence capabilities, Plus Therapeutics is building an integrated CNS oncology platform intended to improve clinical decision-making, accelerate therapeutic development and advance personalized care for patients with CNS cancers.

Similar stocks

Find more stocks like CNSY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.